Here’s Why We’re Not Too Worried About MedAdvisor’s (ASX:MDR) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.

Given this risk, we thought we’d take a look at whether MedAdvisor (ASX:MDR) shareholders should be worried about its cash burn. For the purpose of this article, we’ll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). Let’s start with an examination of the business’s cash, relative to its cash burn.

Check out our latest analysis for MedAdvisor

When Might MedAdvisor Run Out Of Money?

You can calculate a company’s cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. In December 2019, MedAdvisor had AU$16m in cash, and was debt-free. Importantly, its cash burn was AU$8.2m over the trailing twelve months. So it had a cash runway of about 2.0 years from December 2019. Importantly, though, the one analyst we see covering the stock thinks that MedAdvisor will reach cashflow breakeven before then. In that case, it may never reach the end of its cash runway. You can see how its cash balance has changed over time in the image below.

ASX:MDR Historical Debt, March 17th 2020
ASX:MDR Historical Debt, March 17th 2020

How Well Is MedAdvisor Growing?

At first glance it’s a bit worrying to see that MedAdvisor actually boosted its cash burn by 42%, year on year. The silver lining is that revenue was up 22%, showing the business is growing at the top line. Considering the factors above, the company doesn’t fare badly when it comes to assessing how it is changing over time. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years.

Can MedAdvisor Raise More Cash Easily?

Even though it seems like MedAdvisor is developing its business nicely, we still like to consider how easily it could raise more money to accelerate growth. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Many companies end up issuing new shares to fund future growth. By comparing a company’s annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Since it has a market capitalisation of AU$96m, MedAdvisor’s AU$8.2m in cash burn equates to about 8.6% of its market value. That’s a low proportion, so we figure the company would be able to raise more cash to fund growth, with a little dilution, or even to simply borrow some money.

How Risky Is MedAdvisor’s Cash Burn Situation?

It may already be apparent to you that we’re relatively comfortable with the way MedAdvisor is burning through its cash. For example, we think its cash burn relative to its market cap suggests that the company is on a good path. Although its increasing cash burn does give us reason for pause, the other metrics we discussed in this article form a positive picture overall. There’s no doubt that shareholders can take a lot of heart from the fact that at least one analyst is forecasting it will reach breakeven before too long. After taking into account the various metrics mentioned in this report, we’re pretty comfortable with how the company is spending its cash, as it seems on track to meet its needs over the medium term. On another note, MedAdvisor has 5 warning signs (and 1 which makes us a bit uncomfortable) we think you should know about.

Of course MedAdvisor may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.